Australia markets closed

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.7600+0.0100 (+0.57%)
As of 03:10PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close1.7500
Open1.7600
Bid1.6800 x 1000
Ask1.6700 x 2200
Day's range1.7316 - 1.7711
52-week range1.5600 - 2.1600
Volume8,111
Avg. volume27,400
Market cap25.522M
Beta (5Y monthly)1.15
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    ARCA biopharma Announces 2023 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Feb. 01, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported 2023 financial results and provided a corporate update. In April 2022, the Board of Directors establi

  • GlobeNewswire

    ARCA biopharma Announces Third Quarter 2023 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., Oct. 18, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported third quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Dir

  • GlobeNewswire

    ARCA biopharma Announces Second Quarter 2023 Financial Results

    Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options WESTMINSTER, Colo., July 21, 2023 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported second quarter 2023 financial results and provided a corporate update. In April 2022, the Board of Di